Boston Scientific Corp. (BSX) is in the Health Care Industry

• Sort by

• Earnings Preview: Boston Scientific

  Boston Scientific Corporation BSX is scheduled to report Q3 earnings before market open Wednesday, Oct. 22, with a conference call scheduled for 8:00 am ET. Guidance Analysts are expecting a profit of 11c on revenue of $1.97B. The consensus range for EPS is 8c to 12c, with a revenue range...

  External links 2008-10-21

  Tags: Boston Scientific Corp., Revenue, Earnings, Consensus, Seeking Alpha, Operational Accounting, Financial Accounting, Finance, theflyonthewall.com, Healthcare

Additional Resources

• Boston Scientific to Participate in Piper Jaffray Health Care Conference

  NATICK, Mass., Nov. 24 /PRNewswire-FirstCall/ -- Boston Scientific Corporation is scheduled to participate in the Piper Jaffray Health Care Conference, which is being held December 2 - 3 in New York City. Jim Tobin, Chief Executive Officer, will make a 30-minute presentation on Tuesday, December 2,...

  Articles 2008-11-24

• Frost & Sullivan Recognizes Boston Scientific With Stent Market Leadership Award

  Market Prominence through a Wide Product Portfolio, Extensive R&D and Clinical Evaluations MOUNTAIN VIEW, Calif., Nov. 13 /PRNewswire/ -- Based on its recent analysis of the drug eluting stents DES market, Frost & Sullivan recognizes Boston Scientific with the 2008 North American Frost & Sullivan Market Leadership...

  Articles 2008-11-13

• Industry Leaders Highlight Best Practices at Annual Optiant Customer Forum

  Optiant's PowerChainR Delivers 20%+ Inventory Reductions BOSTON, Nov. 12 /PRNewswire/ -- Optiant, the premier provider of inventory planning and inventory optimization solutions, recently held its annual User Forum where customers presented details on how they've leveraged Optiant's PowerChain Suite for significant total supply chain cost savings, better...

  Articles 2008-11-12

• Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials

  CLEVELAND, Nov. 12 /PRNewswire/ -- Intelect Medical, Inc., an early stage company developing an implantable neuromodulation system for stroke and traumatic brain injury recovery, announced it has closed a licensing and financing deal, led by existing investor Boston Scientific Corporation . Existing investor, Greatbatch, Inc. , also...

  Articles 2008-11-12

• FDA Approves Boston Scientific's Apex™ PTCA Dilatation Catheter

  New design provides more options for treating patients with complex lesions NATICK, Mass., Nov. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has received approval from the U.S. Food and Drug Administration to market its ApexTM PTCA(1) Dilatation Catheter. The Apex Catheter is...

  Articles 2008-11-10

• Boston scientific gets good news from the FDA

  The FDA has removed restrictions placed on Boston Scientific that had blocked approval for certain kinds of medical devices, the company recently announced. Restrictions on approving Class III medical devices--devices with the most stringent regulatory requirements--were set in January 2006 when the FDA issued a corporate warning letter...

  Articles 2008-11-01

• Boston Scientific Welcomes Passage of Federal Pain Care Legislation to Benefit Military Members and Veterans

  NATICK, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed passage of legislation to help active members of the U.S. armed forces and service veterans better manage the challenges of chronic pain. The Military Pain Care Act of 2008 was included in the National Defense...

  Articles 2008-10-29

• Zacks Analyst Interview Highlights: St. Jude Medical, Baxter International, Becton, Dickinson, Boston Scientific and CR Bard

  CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Christopher Titus, who discusses St. Jude Medical (NYSE: STJ), Baxter (NYSE: BAX), Becton, Dickinson (NYSE: BDX), Boston Scientific (NYSE: BSX) and CR Bard (NYSE: BCR). Get the most recent insight from Zacks Equity Research...

  Articles 2008-10-28

• UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain

  Confirms clinical value and cost-effectiveness of spinal cord stimulation NATICK, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed an announcement by the U.K.'s National Institute for Health and Clinical Excellence NICE recommending the use of spinal cord stimulation SCS for patients with chronic neuropathic...

  Articles 2008-10-27

• FDA Approves Boston Scientific's Carotid Artery Stent

  Leading carotid stent in Europe and other international markets now available in the United States NATICK, Mass., Oct. 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that the U.S. Food and Drug Administration FDA has approved its Carotid WALLSTENTR MonorailR Endoprosthesis for the treatment of patients...

  Articles 2008-10-23

• Theragenics Corporation Establishes New Product Development Team

  Yem Chin to Lead New Product Development Team BUFORD, Ga. -- Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced the hiring of Mr. Yem Chin as its Lead Product Development Engineer. Mr. Chin and his team will...

  Articles 2008-10-23

• SectorWatch.biz Issues MarketStats on NWCI, ERES, STJ, MDT, BSX, and CSCX

  IRVINE, Calif., Oct. 21 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats for health care technology equities in the news and driving markets today. MarketStats offers a perspective on the aforementioned equities and the opportunity for investors to respond with articles, blogs and opinions. Investors can view...

  Articles 2008-10-21

• Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

  NATICK, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced financial results for the third quarter ended September 30, 2008, as well as guidance for net sales and earnings per share EPS for the fourth quarter of 2008. Third quarter highlights: -- Reported net...

  Articles 2008-10-21

• SectorWatch.biz Issues MarketStats on NWCI, STJ, ERES, BEAT, MDT, and BSX

  IRVINE, Calif., Oct. 20 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats for health care technology equities in the news and driving markets today. MarketStats offers a perspective on the aforementioned equities and the opportunity for investors to respond with articles, blogs and opinions. Investors can view...

  Articles 2008-10-20

• St. Jude Medical Resurrects Former Guidant Plant to Produce Pacemakers in Puerto Rico, an Industrial Info News Alert

  Reported by Annette Kreuger, Industrial InfoResources (Sugar Land, Texas) -- St. Jude Medical Incorporated (NYSE:STJ)(St. Paul, Minnesota) has received final approval from the U.S. Food andDrug Administration to begin producing pacemakers and cardiac leads at anew plant in Arecibo, Puerto Rico. Operating under the company's St. JudeMedical Puerto Rico B.V....

  Articles 2008-10-20

• iNEMI and US FDA Plan Forum on Component Reliability for Medical Electronics

  Meeting to be held November 14 at FDA's White Oak Campus in Silver Spring HERNDON, Va. -- The International Electronics Manufacturing Initiative iNEMI is planning a medical electronics forum to discuss requirements and recommendations developed for the electronics industry to ensure reliability of components used in medical products....

  Articles 2008-10-17

• HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS® Drug-Eluting Stents in Heart Attack Patients

  Landmark trial provides new insight for physicians NATICK, Mass. and WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced results from an analysis of the HORIZONS AMI trial. The HORIZONS AMI trial, sponsored by the Cardiovascular Research Foundation CRF with research grant support from...

  Articles 2008-10-15

• TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated with Second-Generation TAXUS® Liberte® Stent

  NATICK, Mass. and WASHINGTON , Oct. 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced positive one-year results from the Intercontinental and European launch phases of its global TAXUS OLYMPIA registry, the world's largest prospective, post-approval registry for a single drug-eluting stent DES. OLYMPIA is designed to analyze...

  Articles 2008-10-15

• Endeavor® Vs. Taxus®: Medtronic's Drug-Eluting Coronary Stent Linked to Fewer Heart Attacks at Two Years Post Implant

  Latest Data from ENDEAVOR-IV Also Highlight Extremely Low Rates of Very Late Stent Thrombosis with Endeavor DES WASHINGTON -- Two-year results from the ENDEAVOR-IV clinical trial show that the Endeavor drug-eluting stent DES from Medtronic, Inc. (NYSE: MDT), is associated with statistically fewer heart attacks than...

  Articles 2008-10-14